CSL's chief executive says "vaccine fatigue" following the approval of new immunisations against shingles and the cold virus RSV has cut into its influenza vaccine business, but it still managed to outperform the market.
"Given the reduced rates of (influenza) immunisation, there has been ample supply, giving rise to pricing pressure as manufacturers look to clear stock across the industry," CSL chief executive Dr Paul McKenzie said.
